Table 2.
Treatment group (n 26) | Placebo group (n 27) | ||||||||
Baseline examination | Final examination | Baseline examination | Final examination | ||||||
Mean | sd | Mean | sd | Mean | sd | Mean | sd | Significance between groups in RM ANOVA testing assessing (treatment×time) interaction (P) | |
Weight (kg) | 88·2† | 12·1 | 87·3 | 11·9 | 83·1 | 14·8 | 82·8 | 14·5 | NS |
Fat-free mass (%) | 64·7† | 4·26 | 70·31*** | 4·8 | 66·8 | 4·77 | 70·4*** | 4·94 | <0·05 |
Fat mass (%) | 31·63† | 4·58 | 25·67*** | 5·22 | 29·5 | 5·53 | 25·4*** | 5·55 | <0·05 |
Bone mass (%) | 3·6† | 0·47 | 4·02*** | 0·59 | 3·81 | 0·61 | 4·18*** | 0·71 | NS |
Fat-free mass (kg) | 56·9† | 6·68 | 61·1*** | 6·88 | 54·9 | 6·96 | 57·8*** | 7·46 | <0·05 |
Fat mass (kg) | 28·1† | 7·09 | 22·7*** | 7·08 | 25·1 | 8·69 | 21·6*** | 8·15 | <0·05 |
Bone mass (kg) | 3·14† | 0·36 | 3·46*** | 0·38 | 3·1 | 0·36 | 3·34*** | 0·43 | NS |
Power (knee extension) (Nm) | 123† | 27·3 | 140*** | 28·3 | 132 | 27 | 139* | 27·4 | <0·05 |
Sensory motor control (mm) | 1205† | 852 | 477*** | 228 | 1374 | 639 | 516*** | 24 | NS |
RM, repeated measurements; mm, length of path on posturometer.
P<0·05 within the group from baseline to final examination; ***P<0·001 within the group from baseline to final examination.† No significant difference at baseline between treatment group and placebo group.